SCHEMBL18954656

SCHEMBL18954656

CC(C)c1ccc2c(c1)C(=O)C(=O)N2CCC(=O)O

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CASP3 P42574 1/20 0.47
▸ CASP7 P55210 1/20 0.47
▸ PARK7 Q99497 4/20 0.45
▸ ALDH1A1 P00352 6/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ USP5 P45974 1/20 0.43
▸ CUL4A Q13619 1/20 0.43
▸ MAPT P10636 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ ALDH2 P05091 2/20 0.41
▸ ALDH3A1 P30838 2/20 0.41
▸ NR1H3 Q13133 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18954893 0.91 CASP3 (0.41) CASP3CASP7PARK7ALDH1A1KDM4E
SCHEMBL18954622 0.83 PARK7 (0.48) CASP3CASP7PARK7ALDH1A1MAPT
SCHEMBL18954627 0.79 ALDH1A1 (0.54) CASP7ALDH1A1KDM4EHSD17B10MAPT
SCHEMBL15215067 0.78 ALDH1A1 (0.65) CASP3PARK7ALDH1A1MAPTALDH2
SCHEMBL18954848 0.76 PARK7 (0.49) CASP3CASP7PARK7ALDH1A1MAPT
SCHEMBL18954660 0.76 CASP3 (0.57) CASP3CASP7PARK7ALDH1A1CUL4A
SCHEMBL18954857 0.76 CASP3 (0.54) CASP3CASP7PARK7ALDH1A1ALDH2
SCHEMBL18954856 0.76 CASP3 (0.57) CASP3CASP7PARK7
SCHEMBL18954711 0.75 ALDH1A1 (0.73) ALDH1A1KDM4EHPGDHSD17B10CUL4A
SCHEMBL1519990 0.75 CES1 (0.71) PARK7ALDH1A1LMNAALDH2ALDH3A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017099695-A1 N-[(AMINOSULFONYL)PHENYL]-2-(1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)-HYDRAZINECARBOTHIOAMIDE DERIVATIVES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS ISTANBUL UNIVERSITESI REKTORLUGU (TR) 2017-06-15 — — WO disclosed
Send feedback